| Patient | Georgia O'Keeffe |
|---|---|
| Date of birth | 1945-11-15 |
| Identifiers | MRN HR-ET011-SYN; SSN (made up) 000-11-5873 |
| Document date | 2026-03-12 |
| Author | Wendell Ashby, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Retina evaluation of new distortion and blur in the left eye. [S]
Ms. O'Keeffe is seen in the retina clinic two days after her primary care visit, where new distortion and a blurred central spot in the left eye were found on the Amsler grid. Over the past few weeks straight lines on her canvases and door frames have looked bent with the left eye, and small print and fine color differences have become hard to judge. The right eye seems unchanged. She has had no eye pain, redness, flashes, or new floaters. She takes no blood thinners and no other medicines. She paints daily and is afraid of losing the central vision she needs for her work. [S]
| Element | Detail |
|---|---|
| Onset | Over the past few weeks |
| Symptoms | Bent lines and a central blurred spot, left eye; trouble with small print and fine color differences |
| Fellow eye | No change noticed in the right eye |
| Pertinent negatives | No pain, redness, flashes, or new floaters |
| Medicines | None; no anticoagulants |
| Patient concern | Keeping the central vision she needs to paint |
| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Distortion and a central blurred spot in the left eye; no pain, redness, flashes, or floaters |
| Constitutional | Negative | No weight loss or fatigue |
| Neurological | Negative | No headache, double vision, or weakness |
| Psychiatric | Positive | Worried about losing the vision she needs to paint; mood otherwise steady |
4 systems reviewed. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-12 | Body height | 165 | cm | S |
| 2026-03-12 | Body weight | 56 | kg | S |
| 2026-03-12 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-03-12 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-03-12 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-03-12 | Heart rate | 72 | /min | S |
| 2026-03-12 | Respiratory rate | 14 | /min | S |
| 2026-03-12 | Body temperature | 36.5 | Cel | S |
| 2026-03-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-12 | Visual acuity best corrected Right eye by ETDRS eye chart | 78 | {letters} | >=80 | Low | S |
| 2026-03-12 | Visual acuity best corrected Left eye by ETDRS eye chart | 55 | {letters} | >=80 | Low | S |
| 2026-03-12 | Macular grid.center subfield thickness by OCT | 418 | um | 200-300 um | High | S |
| 2026-03-12 | Right eye Intraocular pressure | 15 | mm[Hg] | 10-21 mmHg | Normal | S |
| 2026-03-12 | Left eye Intraocular pressure | 16 | mm[Hg] | 10-21 mmHg | Normal | S |
Vital signs recorded on 2026-03-12; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Visual acuity | Best-corrected 78 letters right and 55 letters left |
| Intraocular pressure | 15 mmHg right and 16 mmHg left before injection |
| Anterior segment | Quiet in both eyes |
| Dilated fundus, left eye | Gray-green subretinal lesion under the fovea with surrounding fluid; large drusen |
| Dilated fundus, right eye | Large drusen and pigment changes; no fluid or hemorrhage |
| OCT | Left eye: subretinal fluid, central subfield thickness 418 µm. Both eyes: large drusen |
| After injection, left eye | Optic nerve head perfused; counts fingers; no pain |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Neovascular (wet) age-related macular degeneration, left eye, with active choroidal neovascularization | active | confirmed | H35.3221 | S — Synthetic modern diagnosis linked to her documented failing eyesight; the historical type of macular degeneration is not recorded. |
| Nonexudative age-related macular degeneration, right eye, intermediate stage | active | confirmed | H35.3112 | S — Synthetic finding in the fellow eye. |
| New distortion (wavy lines) and a blurred central spot with reduced acuity in the left eye; suspected neovascular macular degeneration, urgent retina referral | resolved | confirmed | H53.15 | S — Synthetic presenting concern at the index visit, superseded by the OCT diagnosis at the retina consultation; her failing eyesight is documented (D). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Best-corrected visual acuity (ETDRS letters) | Every injection visit | Completed today | Baseline before treatment: 78 letters right, 55 letters left |
| Imaging | Optical coherence tomography of the macula | Every injection visit | Completed today | Both eyes. Left: subretinal fluid, central subfield thickness 418 µm. Both: large drusen |
| Imaging | Fluorescein angiography or OCT angiography | At diagnosis of suspected neovascular AMD | Deferred | Not performed. OCT and fundus findings were typical, so treatment began the same day without angiography, a departure from the PPP's diagnostic recommendation. Angiography will be done if the response to loading is poor or the picture becomes atypical |
| Examination | Intraocular pressure before and after injection | Every injection visit | Completed today | Before injection 15 mmHg right and 16 mmHg left. After injection the check was by optic nerve perfusion and counting fingers rather than a second pressure reading |
| Examination | Comprehensive dilated eye examination | Every 1 to 2 years at 65 or older | Completed today | Acuity, pressure, slit-lamp, and dilated fundus examination of both eyes today |
| Examination | Dilated examination of the fellow (right) eye | Every injection visit | Completed today | Large drusen; no fluid or hemorrhage |
| Medication safety | Intravitreal injection safety | Every injection visit | Completed today | Povidone-iodine preparation; no complication; first loading dose |
| Self-management | Teaching on warning signs of endophthalmitis and retinal detachment | Every injection visit | Completed today | Taught today with written instructions in large print |
| Self-management | Daily home Amsler grid, each eye | Daily | Completed today | Reviewed her technique with each eye covered in turn |
| Medication safety | AREDS2 supplement for intermediate AMD | Daily, long term | Completed today | Started today; the formula without beta-carotene |
| Survey | Functional vision assessment (reading, color, driving, work) | At diagnosis; again with change | Completed today | Trouble with small print and fine color judgment; drives short routes by day |
| Referral | Low-vision rehabilitation, with home fall-risk review and a driving assessment | Once central vision is reduced; review as vision changes | Referred | Referral sent today |
| Survey | Depression screen (PHQ-2) | At follow-up, because vision loss raises the risk of depression; periodically at 65 or older | Due | Score 1 two days ago; repeat at the July primary care review |
Goal progress:
Guideline basis: Age-Related Macular Degeneration Preferred Practice Pattern (2024); CMID: Clinical Monitoring Intelligence Database, cataract and glaucoma monographs (eye-examination items) (2026)
Follow-up: Retina visit in four weeks for acuity, OCT, pressure, and the second injection. Same-day call for warning signs or new distortion in either eye. Next scheduled visit 2026-04-09: four-week retina follow-up with OCT and second injection. [S]